DE69325393T2 - Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen - Google Patents

Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen

Info

Publication number
DE69325393T2
DE69325393T2 DE69325393T DE69325393T DE69325393T2 DE 69325393 T2 DE69325393 T2 DE 69325393T2 DE 69325393 T DE69325393 T DE 69325393T DE 69325393 T DE69325393 T DE 69325393T DE 69325393 T2 DE69325393 T2 DE 69325393T2
Authority
DE
Germany
Prior art keywords
isobutyramide
treatment
betaglobin
diseases
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69325393T
Other languages
English (en)
Other versions
DE69325393D1 (de
Inventor
Susan Perrine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Childrens Hospital Oakland Research Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Childrens Hospital Oakland Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center, Childrens Hospital Oakland Research Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of DE69325393D1 publication Critical patent/DE69325393D1/de
Application granted granted Critical
Publication of DE69325393T2 publication Critical patent/DE69325393T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69325393T 1992-03-17 1993-03-17 Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen Expired - Fee Related DE69325393T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/852,511 US5439939A (en) 1992-03-17 1992-03-17 Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
PCT/US1993/002389 WO1993018761A1 (en) 1992-03-17 1993-03-17 Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders

Publications (2)

Publication Number Publication Date
DE69325393D1 DE69325393D1 (de) 1999-07-22
DE69325393T2 true DE69325393T2 (de) 1999-12-16

Family

ID=25313524

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69325393T Expired - Fee Related DE69325393T2 (de) 1992-03-17 1993-03-17 Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen

Country Status (10)

Country Link
US (1) US5439939A (de)
EP (1) EP0697862B1 (de)
AT (1) ATE181235T1 (de)
AU (1) AU3810693A (de)
DE (1) DE69325393T2 (de)
DK (1) DK0697862T3 (de)
ES (1) ES2135470T3 (de)
GR (1) GR3031241T3 (de)
SG (1) SG48764A1 (de)
WO (1) WO1993018761A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
IT1273628B (it) * 1993-06-04 1997-07-08 Emerging Pharmaceutical Techno Composizioni farmaceutiche per la cura della talassemia contenenti derivati dell'acido butirrico e in particolare isobutirramide
US5569675A (en) * 1994-03-07 1996-10-29 Bar Ilan University Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
AU774861B2 (en) 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
FR2847817B1 (fr) * 2002-11-28 2006-11-10 Centre Nat Rech Scient Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1658074B1 (de) * 2003-08-01 2012-11-07 Fibrogen, Inc. 2-oxoglutarat-oxygenase-hemmer als induktor des gammaglobins
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
US20070185045A1 (en) * 2006-02-06 2007-08-09 Ratcliffe Peter J Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
MA33899B1 (fr) 2009-12-08 2013-01-02 Hemaquest Pharmaceuticals Inc Procedes et regimes a faible dose pour des troubles des globules rouges
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US20160106821A1 (en) * 2014-10-20 2016-04-21 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
EP3976198A4 (de) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. Verfahren zur behandlung von viral assoziiertem krebs mit histon-deacetylase-inhibitoren
WO2023069529A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482571A (en) * 1982-06-21 1984-11-13 University Of Pittsburgh Sickle cell anemia treatment and compound
US5025029A (en) * 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4822821A (en) * 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
SG86966A1 (en) * 1988-11-29 2002-03-19 Childrens Hosp Medical Center Medicament for augmenting fetal hemoglobin

Also Published As

Publication number Publication date
WO1993018761A1 (en) 1993-09-30
US5439939A (en) 1995-08-08
AU3810693A (en) 1993-10-21
SG48764A1 (en) 1998-05-18
EP0697862A4 (de) 1996-05-29
EP0697862A1 (de) 1996-02-28
ATE181235T1 (de) 1999-07-15
DE69325393D1 (de) 1999-07-22
DK0697862T3 (da) 1999-12-13
ES2135470T3 (es) 1999-11-01
GR3031241T3 (en) 1999-12-31
EP0697862B1 (de) 1999-06-16

Similar Documents

Publication Publication Date Title
DE69325393T2 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
DE3483629D1 (de) 2-pyrimidinyl-l-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
EE200000318A (et) Uudsed ühendid
DE68914488T2 (de) 2-(2-Hydroxy-3-phenoxypropylamino)ethylphenoxyacetamide, Verfahren und Zwischenprodukte zu deren Herstellung.
ATE275562T1 (de) Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
DE69121502D1 (de) Prozess zur darstellung von aspartam aus einem diketopiperazin sowie neue zwischenprodukte und derivate dafür
ATE121949T1 (de) 5,10-methylentetrahydrofolsäure-cyclodextrin- einschlussverbindungen.
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
ATE417831T1 (de) Ceramid ähnliche verbindungen, verfahren zu deren herstellung und deren verwendung als antitumormittel
ATE421961T1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
DE69619868T2 (de) Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung
EP0053695A3 (de) N-Pyrimidinyl-carbaminsäureester, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE59602622D1 (de) Neue pyridin- bzw. pyridazinderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
ATE69809T1 (de) Leukotrienantagonisten, verfahren zu ihrer herstellung, ihre anwendung zur behandlung von krankheiten.
IT1258788B (it) Derivati solforati di acidi biliari
ATE242766T1 (de) Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen
DE69410465T2 (de) Verfahren zur herstellung von thiopyranen
RU94035756A (ru) Производные имидазола, являющиеся ингибиторами питокинов, способы их получения, фармацевтическая композиция

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee